Business Context and Reporting Period
Capricor Therapeutics, Inc. is a development-stage biopharmaceutical company focused primarily on regenerative medicine and cardiovascular therapies. The Form 10-K covers the fiscal year ended December 31, 2014, with audited comparative results for 2013. The company had no product sales or approved commercial products.
Key programs included CAP-1002, an allogeneic cardiosphere-derived cell therapy in the Phase II ALLSTAR trial and Phase I DYNAMIC trial; Cenderitide, in a Phase II heart-failure study; and preclinical exosomes, CU-NP and cardiosphere programs.
Financial Highlights
| Metric | 2014 | 2013 |
|---|---|---|
| Total income | $4.79 million | $0.50 million |
| Collaboration income | $4.17 million | $0 |
| Grant income | $0.62 million | $0.50 million |
| Research and development expense | $7.79 million | $5.20 million |
| General and administrative expense | $3.02 million | $2.21 million |
| Loss from operations | $6.02 million | $6.90 million |
| Net loss | $6.22 million | $8.89 million |
| Net loss per share | $0.53 | $0.85 |
| Cash flow from operating activities | $0.96 million | $(6.14) million |
| Cash flow from financing activities | $5.21 million | $3.93 million |
| Cash and cash equivalents | $8.03 million | $1.73 million |
| Restricted cash | $2.98 million | $1.40 million |
| Working capital | $5.31 million | $1.63 million |
| Total liabilities | $19.88 million | $6.07 million |
| Stockholders’ equity (deficit) | $(6.25) million | $(0.53) million |
The filing does not provide a meaningful product margin because the company had no product revenue. Operating expenses totaled $10.80 million, and the reported income primarily reflected grant income and recognition of a portion of the $12.5 million Janssen payment received in January 2014. Approximately $8.33 million of the Janssen payment remained deferred at year-end.
Material Changes Versus the Prior Comparable Period
- Income increased primarily because $4.17 million of Janssen collaboration income was recognized in 2014; no collaboration income was recognized in 2013.
- R&D expense increased $2.59 million, driven by active CAP-1002 clinical development, manufacturing and clinical costs, Janssen chemistry, manufacturing and controls work, and Cenderitide activities.
- G&A expense increased approximately $0.81 million, principally from higher compensation, recruiting, professional fees and public-company compliance costs.
- Net loss improved by approximately $2.68 million, primarily because 2013 included a $1.92 million goodwill impairment charge and 2014 included Janssen collaboration income.
- Cash increased by approximately $6.31 million, primarily from the Janssen payment and CIRM loan disbursements. This improvement does not indicate recurring operating profitability.
- CIRM loan payable increased to $9.16 million, with $0.26 million of accrued interest. The loan carries repayment obligations, potential interest and a risk premium of up to 500% of the loan amount upon specified revenue thresholds, subject to the agreement’s terms.
Guidance, Outlook, Risks and Unusual Items
- Management expected 2015 CAP-1002 development spending of approximately $10.0 million to $14.0 million, primarily for ALLSTAR and DYNAMIC, and Cenderitide development spending of approximately $1.0 million to $2.0 million.
- The company expected continued substantial losses and stated that it would require significant additional capital to fund operations and clinical development.
- In January and February 2015, after year-end, the company raised approximately $17.05 million through two private placements totaling 4,497,867 shares. These financings are material subsequent events and dilute existing holders.
- Janssen held an exclusive option to license CAP-1002 and related technologies. If exercised, potential upfront and milestone payments could total up to $325 million, plus royalties; the filing provides no assurance that Janssen would exercise the option.
- CAP-1002 remained investigational. ALLSTAR was an estimated 300-patient Phase II study, DYNAMIC Phase I enrollment began in December 2014, and a DMD clinical program was planned subject to IND authorization.
- Cenderitide received FDA Fast Track designation for the post-acute heart-failure indication, but regulatory approval was not assured.
- The company relied on Cedars-Sinai Medical Center for laboratory and GMP manufacturing facilities. Loss of access could require substantial investment and delay clinical development.
- Major risks included clinical-trial failure or delay, adverse immune reactions, regulatory rejection, manufacturing or donor-heart supply problems, dependence on licensors and collaborators, intellectual-property challenges, competition, and the need for additional financing.
- Related-party arrangements included leases and intellectual-property agreements with Cedars-Sinai, which held more than 10% of the company’s stock. No material legal proceedings were reported.
Investor Verification Items
- Verify the composition and remaining recognition period of the $12.5 million Janssen payment, including the $8.33 million deferred revenue balance.
- Review the CIRM loan agreement for repayment, forgiveness, milestone, interest and potential risk-premium provisions, and confirm remaining available disbursements.
- Assess liquidity after incorporating the $17.05 million of 2015 equity financings, planned 2015 R&D spending and ongoing operating losses.
- Track ALLSTAR enrollment, six-month and twelve-month results, DYNAMIC safety data, and the timing and outcome of any DMD IND submission.
- Evaluate the probability and economics of Janssen exercising its CAP-1002 license option.
- Review dilution from the 5.00 million outstanding options and 303,881 outstanding warrants at December 31, 2014, as well as subsequent equity issuances.
- Confirm continued access to Cedars-Sinai manufacturing facilities and compliance with applicable GMP, FDA and state licensing requirements.